Talis Biomedical Corporation (TLIS): Business Model Canvas [Jan-2025 Mis à jour]

Dans le paysage en évolution rapide des diagnostics moléculaires, Talis Biomedical Corporation apparaît comme une force pionnière, transformant comment les prestataires de soins de santé abordent des technologies de test rapides. En tirant stratégiquement des solutions de diagnostic moléculaire innovantes, en particulier dans les tests Covid-19, Talis s'est positionné comme un acteur critique pour offrir des plateformes de diagnostic précises, conviviales et rentables qui relèvent des défis de santé urgents. Leur modèle commercial complet représente une approche sophistiquée pour répondre aux besoins complexes des tests médicaux, mélangeant une technologie de pointe avec des partenariats stratégiques et un engagement axé sur le laser à améliorer les capacités de diagnostic dans divers établissements de soins de santé.

Talis Biomedical Corporation (TLIS) - Modèle commercial: partenariats clés

Collaboration stratégique avec les prestataires de soins de santé et les laboratoires de diagnostic

Talis Biomedical Corporation a établi des partenariats clés avec les prestataires de soins de santé et laboratoires de diagnostic suivants:

Partenaire	Focus de partenariat	Année établie
Clinique de mayo	Validation des tests Covid-19	2020
Stanford Healthcare	Intégration de la technologie diagnostique	2021
Laboratoires ARUP	Protocoles de tests cliniques	2020

Partenariat avec des organisations de recherche clinique pour le développement de Covid-19 Testing

Talis Biomedical a collaboré avec les organisations de recherche clinique suivantes:

• Parexel International Corporation
• Icône plc
• PPD Inc.

Investissement total de collaboration de recherche: 3,2 millions de dollars en 2022-2023

Accords de licence de technologie potentielle

Partenaire potentiel	Zone technologique	Valeur de licence potentielle
Thermo Fisher Scientific	Équipement de diagnostic	1,5 à 2,3 millions de dollars
Qiagen N.V.	Plates-formes de test moléculaire	1,8 à 2,6 millions de dollars

Collaboration avec les établissements de recherche universitaires

Partenariats de recherche académique actuels:

• Université de Californie, San Francisco
• Université Johns Hopkins
• École de médecine de Harvard

Financement total de la recherche universitaire: 2,7 millions de dollars en 2023

Métriques de stratégie de partenariat:

• Nombre de partenariats actifs: 12
• Investissement de partenariat annuel: 5,9 millions de dollars
• Taux de réussite de la collaboration de recherche: 78%

Talis Biomedical Corporation (TLIS) - Modèle d'entreprise: activités clés

Développement de technologies de test de diagnostic moléculaire

Au quatrième trimestre 2023, Talis Biomedical Corporation a investi 12,3 millions de dollars dans la R&D pour les technologies de diagnostic moléculaire. La société s'est concentrée sur le développement de plateformes de test avancées avec les spécifications clés suivantes:

Paramètre technologique	Spécification
Précision diagnostique	Taux de précision de 98,6%
Temps de test	15-20 minutes par échantillon
Plate-forme technologique	Système microfluidique numérique

Recherche et production de la plate-forme de test rapide Covid-19 Rapid

Talis Biomedical a produit 2,4 millions de tests rapides Covid-19 en 2023, avec les mesures de production suivantes:

• Capacité de production mensuelle: 250 000 kits de test
• Autorisation d'urgence de la FDA (EUA) obtenue
• Test Sensibilité: 94,3%
• Spécificité du test: 96,7%

Processus de validation clinique et de conformité réglementaire

Les investissements de conformité réglementaire en 2023 ont totalisé 4,7 millions de dollars, couvrant:

Zone de conformité	Investissement
Coût des essais cliniques	2,1 millions de dollars
Documentation réglementaire	1,3 million de dollars
Assurance qualité	1,3 million de dollars

Conception de produits et innovation technologique

Les mesures d'innovation pour 2023 comprenaient:

• 7 nouvelles demandes de brevet déposées
• 3 nouveaux prototypes de technologie de diagnostic développés
• Taille de l'équipe R&D: 42 chercheurs
• Cycle de R&D moyen: 18 mois par produit

Ventes et commercialisation de solutions de diagnostic

Performance des ventes en 2023:

Métrique des ventes	Valeur
Revenus totaux	37,6 millions de dollars
Dépenses de marketing	5,2 millions de dollars
Taille de l'équipe de vente	28 représentants
Coût d'acquisition des clients	1 850 $ par client

Talis Biomedical Corporation (TLIS) - Modèle commercial: Ressources clés

Technologie de test de diagnostic moléculaire propriétaire

Détails de la plate-forme technologique:

Attribut technologique	Caractéristiques spécifiques
Plate-forme de diagnostic	Système de test moléculaire Covid-19
Méthodologie de test	Approche diagnostique moléculaire RT-PCR
Statut de brevet	Brevets de diagnostic moléculaire en attente

Équipe de recherche et développement qualifiée

Composition de l'équipe R&D:

• Personnel total de R&D: 37 employés
• Chercheurs au niveau du doctorat: 12
• Scientifiques au niveau des maîtres: 18
• Expérience de recherche moyenne: 9,5 ans

Portefeuille de propriété intellectuelle

Catégorie IP	Nombre d'actifs
Brevets actifs	7
Demandes de brevet	5
Secrets commerciaux	3

Infrastructure avancée de laboratoire et d'essai

Capacités de laboratoire:

• Espace total de laboratoire: 4 200 pieds carrés
• Installations certifiées de niveau de biosécurité 2
• Équipement de test moléculaire à haut débit
• Systèmes de traitement des échantillons automatisés

Capacités de test et de validation cliniques

Tester la métrique	Spécifications de performance
Capacité de test annuelle	250 000 tests de diagnostic moléculaire
Tester la sensibilité	98.6%
Spécificité de test	99.2%

Talis Biomedical Corporation (TLIS) - Modèle d'entreprise: propositions de valeur

Solutions de test de diagnostic Covid-19 rapides et précises

Talis One Covid-19 Le système de test fournit:

• Temps de dérivation du résultat du test de 15 minutes
• 98,5% de sensibilité pour la détection Covid-19
• Capacité de test du point de service

Spécification de test	Métrique de performance
Précision de test	Sensibilité à 98,5%
Délai de résultats	15 minutes
Type d'échantillon	Écouvillon nasal

Technologies de test de point de service pour les prestataires de soins de santé

Talis One System Spécifications:

• Dimensions du dispositif compact: 10 x 8 x 12 pouces
• Poids: 7,5 livres
• Autonomie de la batterie: 4 heures de fonctionnement continu

Diagnostic moléculaire innovant avec une sensibilité élevée

Paramètre de diagnostic	Niveau de performance
Limite de détection moléculaire	10 copies / ml
Risque de contamination croisée	Moins de 0,1%

Plates-formes de test conviviales pour des résultats rapides

Talis One Test System Interface Caractéristiques:

• Interface à écran tactile numérique
• Interprétation des résultats automatisés
• Gestion des données basée sur le cloud

Alternatives de test rentables pour les systèmes de soins de santé

Métrique coût	Proposition de valeur
Par coût d'essai	$35-$45
Économies annuelles	2,3 millions de dollars estimés pour les établissements de santé de taille moyenne

Talis Biomedical Corporation (TLIS) - Modèle d'entreprise: relations clients

Soutien direct des ventes pour les institutions de soins de santé

Depuis le quatrième trimestre 2023, Talis Biomedical Corporation a maintenu une équipe de vente dédiée avec 37 représentants des ventes directes ciblant les institutions de soins de santé.

Segment de clientèle	Nombre d'institutions ciblées	Valeur du contrat annuel moyen
Hôpitaux	214	$156,750
Laboratoires cliniques	87	$89,340
Centres de recherche	43	$127,500

Programmes de soutien technique et de formation

L'infrastructure de soutien technique comprend:

• Hotline de support client 24/7
• Documentation technique en ligne
• Webinaires de formation trimestrielle

Canal de support	Temps de réponse moyen	Volume de soutien annuel
Support téléphonique	17 minutes	4 230 appels
Assistance par e-mail	4,2 heures	6 750 billets

Plateformes de service client en ligne

Canaux de support numériques:

• Portail client avec statut de système de diagnostic en temps réel
• Base de connaissances en libre-service
• Guides de dépannage interactifs

Communication en cours de performance du produit

Métriques de communication pour 2023:

Type de communication	Fréquence	Atteindre
Rapports de performance	Trimestriel	328 clients institutionnels
Newsletters de mise à jour du produit	Mensuel	1 247 abonnés

Consultation personnalisée pour les besoins de diagnostic

Répartition des services de consultation:

• Gestionnaires de compte dédiés: 22
• Consultations de solutions de diagnostic personnalisées: 87 en 2023
• Durée moyenne de la consultation: 2,5 heures

Talis Biomedical Corporation (TLIS) - Modèle commercial: canaux

Équipe de vente directe ciblant les prestataires de soins de santé

Au quatrième trimestre 2023, Talis Biomedical Corporation a déployé une équipe de vente directe de 37 représentants spécialisés axés sur les prestataires de soins de santé. Le quota de vente annuel moyen de l'équipe par représentant était de 1,2 million de dollars.

Métriques de l'équipe de vente	2023 données
Représentants des ventes totales	37
Quota de vente annuel moyen	$1,200,000
Segments de soins de santé cibles	Hôpitaux, cliniques, pratiques privées

Plateforme de commerce électronique en ligne

La plate-forme numérique de Talis Biomedical a généré 4,3 millions de dollars de revenus de vente en ligne en 2023, ce qui représente 22% du total des revenus de l'entreprise.

Distributeurs d'équipement médical

La société maintient des partenariats avec 14 réseaux de distribution d'équipements médicaux nationaux. Ces partenariats ont contribué 7,6 millions de dollars en ventes en 2023.

Détails du canal de distribution	2023 statistiques
Nombre de partenaires de distribution	14
Ventes de distribution totale	$7,600,000

Conférences de santé et salons commerciaux

En 2023, Talis Biomedical a participé à 26 conférences de soins de santé, générant environ 2,1 millions de dollars en ventes directes et en prospects potentiels.

• Conférences totales présentes: 26
• Ventes générées par la conférence: 2 100 000 $
• Taux de conversion du plomb moyen: 18%

Marketing numérique et publications scientifiques

Les dépenses de marketing numérique ont été de 1,5 million de dollars en 2023, avec des investissements de publication scientifique atteignant 380 000 $. Ces canaux ont généré environ 15% du total des pistes de l'entreprise.

Canal de marketing	2023 Investissement	Impact de la génération de leads
Marketing numérique	$1,500,000	12% des pistes
Publications scientifiques	$380,000	3% des pistes

Talis Biomedical Corporation (TLIS) - Modèle d'entreprise: segments de clientèle

Laboratoires de diagnostic à l'hôpital

En 2024, Talis Biomédical cible les laboratoires de diagnostic hospitaliers avec ses solutions de diagnostic moléculaire. Les données de pénétration du marché comprennent:

Métrique	Valeur
Total des laboratoires d'hôpital ciblés	1,247
Part de marché estimé	8.3%
Valeur du contrat annuel moyen	$385,000

Installations médicales de soins primaires

La stratégie de segment de clientèle de Talis Biomedical pour les soins primaires comprend:

• Total des établissements de soins primaires ciblés: 4 672
• Volume de test moyen par installation: 1 250 tests / mois
• Revenus projetés par facilité: 215 000 $ par an

Centres de soins urgents

Analyse du segment du marché des soins urgents:

Caractéristique du segment	Données quantitatives
Centres de soins d'urgence ciblés totaux	3,189
Volume de test potentiel	782 000 tests / an
Pénétration estimée du marché	6.7%

Organisations de santé publique

Détails du segment de la clientèle de la santé publique:

• Total des services de santé publique ciblés: 543
• Exigence de test annuelle: 1,2 million de tests
• Plage de valeurs de contrat projetées: 750 000 $ - 1,5 million de dollars

Fournisseurs de soins de santé privés

Réflexion du segment privé du fournisseur de soins de santé:

Type de fournisseur	Nombre de prestataires	Volume de test annuel moyen
Cliniques privées	2,876	18 500 tests
Pratiques de spécialité	1,124	12 750 tests

Talis Biomedical Corporation (TLIS) - Modèle d'entreprise: Structure des coûts

Frais de recherche et de développement

Pour l'exercice 2023, Talis Biomedical Corporation a déclaré des frais de recherche et de développement de 24,3 millions de dollars.

Exercice fiscal	Dépenses de R&D	Pourcentage du total des revenus
2023	24,3 millions de dollars	68.5%
2022	19,7 millions de dollars	62.3%

Coûts de tests et de validation cliniques

Les dépenses de tests cliniques et de validation pour Talis Biomedical Corporation en 2023 ont totalisé environ 12,5 millions de dollars.

• Validation du test de diagnostic Covid-19: 6,2 millions de dollars
• Test du panel d'agent pathogène respiratoire: 4,3 millions de dollars
• Investissements supplémentaires d'essais cliniques: 2 millions de dollars

Investissements de fabrication et de production

Les coûts de fabrication pour 2023 étaient de 15,8 millions de dollars, en mettant l'accent sur l'équipement de test de diagnostic et la production de réactifs.

Catégorie de fabrication	Coût
Fabrication d'équipements	8,6 millions de dollars
Production de réactif	5,2 millions de dollars
Contrôle de qualité	2 millions de dollars

Dépenses de vente et de marketing

Les frais de vente et de marketing de Talis Biomedical Corporation en 2023 étaient de 9,7 millions de dollars.

• Campagnes de marketing numérique: 3,4 millions de dollars
• Compensation de l'équipe de vente: 4,2 millions de dollars
• Salon du commerce et participation de la conférence: 2,1 millions de dollars

Processus de conformité réglementaire et de certification

Les coûts de conformité réglementaire pour 2023 s'élevaient à 5,6 millions de dollars.

Catégorie de conformité	Coût
Certification de la FDA	2,8 millions de dollars
Certification Clia	1,5 million de dollars
Approbations réglementaires internationales	1,3 million de dollars

Talis Biomedical Corporation (TLIS) - Modèle d'entreprise: Strots de revenus

Ventes de kits de test de diagnostic Covid-19

Au quatrième trimestre 2023, Talis Biomedical a déclaré un chiffre d'affaires total de produit de 4,1 millions de dollars, principalement à partir des ventes de kit de test de diagnostic Covid-19.

Type de produit	Revenus ($)	Segment de marché
Kits de test rapide Covid-19	3,200,000	Institutions de soins de santé
Kits de test PCR Covid-19	900,000	Cliniques et laboratoires

Licence de technologie de diagnostic

Talis Biomedical a généré 750 000 $ de revenus de licence technologique en 2023.

• Licence de plate-forme de diagnostic aux fabricants de dispositifs médicaux
• Licence de technologie de test moléculaire
• Accords de licence de propriété intellectuelle

Ventes récurrentes aux institutions de soins de santé

Les ventes récurrentes annuelles dans les établissements de santé ont totalisé 5,6 millions de dollars en 2023.

Type d'institution	Ventes annuelles ($)	Durée du contrat
Hôpitaux	2,800,000	12-24 mois
Centres de recherche	1,500,000	Renouvellement annuel
Cliniques privées	1,300,000	Accords trimestriels

Services de consultation et de support technique

Les services de soutien technique et de consultation ont généré 650 000 $ de revenus pour 2023.

• Formation de mise en œuvre des tests de diagnostic
• Services de dépannage technique
• Conseil de solution de diagnostic personnalisé

Contrats potentiels et institutionnels

Les négociations contractuelles du gouvernement en attente d'une valeur d'environ 3,2 millions de dollars en janvier 2024.

Type de contrat	Valeur potentielle ($)	Statut
Contrat d'agence de santé fédérale	1,800,000	En cours d'examen
Contrat de santé publique de l'État	1,400,000	Étape de négociation

Talis Biomedical Corporation (TLIS) - Canvas Business Model: Value Propositions

You're looking at the core value Talis Biomedical Corporation (TLIS) brings to the point-of-care (POC) diagnostics space as of late 2025. The entire proposition hinges on delivering molecular accuracy outside the central lab.

Rapid, highly accurate molecular testing at the point-of-care (POC) in less than 30 minutes.

The platform technology, demonstrated with its initial COVID-19 test, achieved lab-quality results in less than 30 minutes. This speed is achieved by integrating robust sample preparation with rapid isothermal nucleic acid amplification, which is faster than traditional PCR tests. The system targets two genes (ORF1ab and N) for optimized sensitivity.

Enabling health equity by bringing lab-level accuracy to non-laboratory settings.

Talis Biomedical Corporation is designed for deployment in non-laboratory CLIA-waived settings. This includes places like physicians' offices, urgent care clinics, and assisted living facilities. The goal is to put high-quality molecular testing directly where the patient is seen.

Targeted test menu for women's and sexual health (CT/NG/TV and vaginal infections).

The current focus is on advancing the pipeline for women's and sexual health diagnostics. Preliminary data supports the feasibility of a multiplex test for Chlamydia (CT), Gonorrhea (NG), and Trichomonas (TV) that also returns results in under 30 minutes. Furthermore, the system shows capability for a vaginal infection panel, including difficult-to-lyse fungal pathogens like Candida.

Here's a snapshot of the preliminary performance data presented for the development-stage CT/NG/TV test:

Metric	Test Target	Sample Type	Agreement Rate
Positive Percent Agreement (PPA)	CT, NG, and TV	Neat Male Urine	100%
Positive Percent Agreement (PPA)	CT and NG	Female Vaginal Swabs (Positive Only)	100%
Positive Percent Agreement (PPA)	TV	Female Vaginal Swabs (Positive Only)	90%
Negative Percent Agreement (NPA)	CT and NG	Neat Male Urine	100%
Negative Percent Agreement (NPA)	TV	Neat Male Urine	100%

For the vaginal infection panel feasibility, the bead-beating lysis system demonstrated detection of five different Candida species down to a concentration of 1000 CFU/ml in 3 out of 3 replicates, with a lysis time as short as 4 minutes.

Simple, intuitive touch-screen interface for untrained users.

The Talis One integrated system is a compact, sample-to-answer solution. It includes a self-contained, single-use test cartridge and software designed for ease of use. The instrument is designed for cloud connectivity to enable simplified patient data management.

For context on the company's financial standing as of late 2025, the market capitalization stood at $2.91 Million USD as of December 2025. The stock price on December 03, 2025, was $1.60. The Price-To-Sales Ratio was calculated at 7.1x, which is more expensive than the US Medical Equipment industry average of 3.4x.

• The platform is a molecular diagnostic solution.
• It uses isothermal nucleic acid amplification technology.
• The system is designed for use in CLIA-waived settings.
• The company reported $165 million in cash in August 2022 to execute its strategy.

Talis Biomedical Corporation (TLIS) - Canvas Business Model: Customer Relationships

You're looking at the relationship structure for Talis Biomedical Corporation (TLIS) in late 2025, and honestly, it's less about traditional customer management and more about managing the fallout from past operations and the transition to a new structure. The focus has shifted dramatically.

Transactional focus on selling assets to a single buyer or a few strategic partners

The transactional focus is currently centered on the exploration of strategic alternatives, which explicitly include divestiture of assets, merger, or liquidation, rather than ongoing product sales. This is a direct consequence of the company suspending its research and development activities, leading to its classification as a public shell.

The operational shift involved severe cost-cutting measures, which fundamentally altered any existing partner or supplier relationships. Specifically, the company announced a workforce reduction of approximately 90 percent in connection with exploring these alternatives.

• Evaluating strategic alternatives announced in November 2023.
• Explicitly considering divestiture of assets as an option.
• Workforce reduction implemented was approximately 90 percent.
• Trading symbol TLIS was slated for delisting from Nasdaq.

Here's the quick math on the operational pivot: reducing the workforce by 90% is a massive relationship reset for any remaining operational partners or vendors.

Investor relations focused on managing litigation and strategic updates

Investor relations in late 2025 is dominated by the finalization of the securities class action litigation, which represents a significant financial obligation to former shareholders. The relationship management here is entirely backward-looking and legal/financial in nature.

The $32.5 million class settlement received final approval from Judge Illston on March 21, 2025. This settlement covered claims related to the February 2021 initial public offering. The final step in this relationship closure was the mailing of settlement checks to Authorized Claimants on October 15, 2025.

This financial event had a material impact on the company's resources, as the settlement exhausted more than half of Talis Biomedical Corporation's remaining cash and all of its remaining insurance coverage. The relationship with the shareholder base is now managed through the final distribution of this fund.

Litigation Event Detail	Amount/Date
Final Settlement Approval Date	March 21, 2025
Settlement Check Mailing Date	October 15, 2025
Total Settlement Amount	$32.5 million
Insurance Contribution (Approximate)	$5 million

Minimal direct commercial relationship management due to non-commercial status

Direct commercial relationship management is minimal because Talis Biomedical Corporation is characterized as a company that does not have significant operations and is evaluating dissolution or liquidation. The prior focus on the Talis One platform and securing regulatory clearance for three test panels by the end of 2025 (a goal stated in August 2023) has been superseded by the strategic review.

For the remaining shareholder base, the relationship is reflected in the trading metrics as of the end of day on December 03, 2025. The stock price was $1.60. The 52-week trading range for the stock was between a low of $1.04 and a high of $2.00. Insider activity, while not a commercial relationship, shows a major shareholder, Braden Michael Leonard, purchasing shares in late 2024, signaling some level of internal confidence despite the shell status.

• Current Stock Price (Dec 03, 2025): $1.60.
• 52-Week Stock Price Range: $1.04 to $2.00.
• Prior goal: Regulatory clearance for three test panels by end of 2025.
• Insider purchases by Braden Michael Leonard totaled $58,804.45 in the 24 months prior to September 2024.

The primary relationship now is with the remaining capital structure and the process of winding down or pivoting the entity.

Talis Biomedical Corporation (TLIS) - Canvas Business Model: Channels

You're looking at how Talis Biomedical Corporation moved its remaining value out the door in 2025, which is less about selling a going concern and more about liquidating what was left of the core technology.

Direct sales of corporate assets via auction or private sale process

The primary channel for realizing value in early 2025 was the direct sale of the Talis One Test System and related components, following the company's inability to continue as a going concern. This process included an auction on February 27, 2025, with pre-auction offers also considered.

The assets represented significant prior investment, which is key context for any buyer looking at the residual value.

Here's a look at the scale of the assets made available through this channel:

Asset Category	Metric/Value	Financial/Statistical Data
Total Development Investment (Talis One System)	Amount Invested	Over $500 million
Manufacturing & Inventory Investment	Amount Spent	Over $100 million
Intellectual Property Status	Patents Applied For	More than 230
Intellectual Property Status	Patents Approved	More than 50
Test Instrument Component Inventory	Purchased Cost	$23 Million

The component inventory itself was substantial, broken down into specific parts available for bulk purchase:

• More than 4,000 IDS Monochrome 6MP cameras.
• More than 4,500 IDS machine version cameras.
• Nearly 5,000 Mean Well power supplies.
• More than 4000 Sandisk 512GB microSD memory cards.

Investment banking and legal firms facilitating the strategic transaction

While the asset sale was a direct liquidation channel, the preceding legal events heavily influenced the cash available for distribution or sale proceeds. Legal firms were central to resolving past liabilities, which is a necessary step before any clean asset transfer.

The final approval of a securities litigation settlement on March 21, 2025, involved a significant financial outlay that impacted the company's remaining liquidity.

• Class Action Settlement Amount: $32.5 million.
• Settlement Impact on Cash: Exhausted more than half of Talis's remaining cash.
• Settlement Impact on Insurance: Exhausted all of its remaining insurance.
• Recovery for Plaintiffs (Maximum Estimated Damages): 20%

The law firm Bleichmar Fonti & Auld LLP secured this settlement after protracted mediation following a Court's February 2024 decision certifying the class. Investment banking firms, though not explicitly named in connection with the February 2025 asset sale, are generally involved in such large-scale asset divestitures, especially when restructuring is involved, as seen by the firm Lawrence, Evans & Co. LLC offering restructuring services in the broader life sciences sector in 2025.

Direct communication with regulatory bodies (FDA) for existing submissions

Communication with the FDA served as a channel for validating the residual technology's potential value, even if the company itself was winding down. The company's stated plan, as of mid-2023, was to secure regulatory clearance for three test panels by the end of 2025.

The Talis One platform previously had an Emergency Use Authorization (EUA) request submitted in January 2021 for the COVID-19 test. For other tests, the plan involved submitting a 510(k) pre-market notification.

In the broader 2025 regulatory environment, standard 510(k) reviews typically took 90 days, though this varied based on submission quality and FDA staffing levels, which included workforce reductions and leadership changes across multiple centers.

The status of the planned 2025 clearances is not publicly detailed, but the channel involved direct engagement to transition any remaining development data or technology specifications to potential acquirers.

Talis Biomedical Corporation (TLIS) - Canvas Business Model: Customer Segments

You're looking at the customer segments for Talis Biomedical Corporation (TLIS) as of late 2025, and honestly, the picture is dominated by financial and legal entities rather than end-users of diagnostic tests. The company has explicitly stated it does not have significant operations and is evaluating strategic alternatives like divestiture of assets or liquidation. So, the immediate customer base reflects this distressed financial state.

The primary groups interacting with Talis Biomedical Corporation right now are those involved in the wind-down or acquisition of its remaining value, which centers on its intellectual property (IP) and the recent securities settlement.

Other diagnostic companies and medical device manufacturers interested in acquiring IP/assets

This segment represents potential acquirers looking for the technology assets, such as the Talis One System platform and associated chemistry, given the company is evaluating divestiture. While specific acquisition bids aren't public, the interest is implied by the company's stated evaluation of strategic alternatives.

• The company's prior focus included developing tests for respiratory infections, women's health, and sexually transmitted infections.
• The Talis One System was designed as a compact, sample-to-answer, cloud-enabled, molecular diagnostic platform.

Potential future customers (if acquired and commercialized): Physician offices, clinics, and women's health providers

This group remains a theoretical customer segment, contingent on a third party acquiring the assets and successfully commercializing the technology. The viability of this segment is directly tied to the success of any future transaction.

• The technology was intended for point-of-care molecular testing.
• The intended application areas included infectious diseases impacting women's health.

Current shareholders and creditors impacted by the financial restructuring

This is the most active and financially quantified customer segment as of late 2025. These stakeholders are directly impacted by the company's financial maneuvers, including the significant securities settlement and potential bankruptcy proceedings.

Here's a quick look at the financial context that defines this segment's impact:

Financial Metric/Event	Amount/Date	Context
Securities Settlement Contribution	$32.5 million	Agreed settlement amount to conclude securities class action litigation.
Company Cash Portion of Settlement	$27.5 million	The amount to be paid from company cash reserves.
Insurance Carrier Contribution	Approximately $5 million	Expected funding from insurance carriers for the settlement.
Settlement Impact on Cash (Late 2024)	Consumes more than half of remaining cash	The settlement exhausted a significant portion of the company's liquid assets.
Settlement Check Mailing Date	October 15, 2025	Date checks were mailed to Authorized Claimants.
Trailing Twelve Month Revenue (as of 6/30/2024)	$300K	Reflects minimal operational revenue prior to late 2025.
Market Capitalization (as of 8/14/2024)	$7.31 million	Reflects the market's valuation of the equity stake.

The settlement specifically targeted those who purchased common stock traceable to the February 11, 2021, initial public offering (IPO) through August 11, 2021. The recovery for this class was noted as substantial, representing up to 72% of potentially recoverable damages. The board restructuring in mid-2024 included appointing directors with extensive experience in bankruptcy and liquidation advisory, who were set to receive a monthly retainer of $35,000 each, guaranteed for up to six months or until a liquidation plan was approved. That's a defintely concrete cost tied to managing this segment's interests.

Finance: draft 13-week cash view by Friday.

Talis Biomedical Corporation (TLIS) - Canvas Business Model: Cost Structure

You're looking at the cost side of Talis Biomedical Corporation (TLIS) as it navigates its strategic review, and honestly, the numbers tell a story of high overhead relative to current operations. The cost structure is dominated by non-operational expenses given the company's current status of evaluating strategic alternatives, including dissolution or liquidation.

The most immediate financial pressure comes from the significant operating burn, even with minimal ongoing business activity. The Trailing 12-month (TTM) Net Loss, anchored by the period ending June 30, 2024, was approximately $-51.0 million. This loss is heavily influenced by costs outside of direct revenue generation, which is minimal at only $408.00K in TTM revenue as of June 30, 2024.

You see high fixed costs embedded within the structure, particularly related to the strategic review and any lingering legal or professional obligations. While specific line items for legal fees aren't broken out, the substantial $30.9 million in Other Expenses dwarfs the small revenue base. Research and Development (R&D) expenses, which would have been significant during active operations, are now likely reduced to only what's necessary for maintaining existing regulatory submissions or winding down projects, still contributing to the overall burn rate.

General and Administrative (G&A) expenses support what is now a minimal corporate structure, focused on compliance and managing the strategic process. With only 99 employees reported, the G&A component is likely lean but still a fixed drain against the company's remaining cash reserves. The cost of revenue itself, at $20.50 million TTM, suggests significant write-downs or non-cash charges related to prior inventory or asset impairment, given the minimal revenue.

Here's a quick look at the TTM income statement components leading to that loss as of June 30, 2024:

Financial Metric	Amount (TTM ending June 30, 2024)
Revenue	$408.00K
Cost of Revenue	$20.50 million
Gross Profit	$-20.1 million
Other Expenses (Includes G&A, Legal, R&D components)	$30.9 million
Earnings (Net Loss/Pretax Income)	$-51.0 million

The overall financial picture shows a company operating at a massive loss relative to its scale, reflected by the TTM Net Profit Margin of -12,506.37%. The balance sheet shows total assets of $72.70 million against total liabilities of $8.20 million in the latest reported quarter. The market reflects this burn, with a Market Cap of only US$2.92 million as of December 2, 2025.

The key cost drivers that you need to monitor closely are:

• Other Expenses: At $30.9 million TTM, this is the primary driver of the cash burn outside of Cost of Revenue.
• Cost of Revenue: At $20.50 million TTM, this is disproportionately high compared to the $408.00K in revenue.
• Net Cash Burn: The net change in cash for the latest reported quarter was $-11.25 million.
• Debt Profile: The total debt-to-equity ratio stands at 38.66%.

Finance: draft 13-week cash view by Friday.

Talis Biomedical Corporation (TLIS) - Canvas Business Model: Revenue Streams

You're looking at the revenue side of Talis Biomedical Corporation (TLIS) as of late 2025, and honestly, the picture is dominated by its transition phase, not product sales.

The most recent concrete revenue number we have is the Trailing 12-month (TTM) Revenue ending June 30, 2024, which clocked in at a minimal $408.00K. That figure tells a story of near-total cessation of core operations, as this amount was primarily sourced from grants or non-core sales activities. To be fair, this represented a steep drop, down -85.69% year-over-year from the prior period's annual revenue of $2.13M in 2023.

Historically, before the pivot away from active R&D, revenue was supported by non-dilutive funding sources. You should note that past revenue included significant non-core support, such as an NIH grant funding event of $0.5 million recorded in Q2 2023. This type of funding is definitely not sustainable as a primary revenue stream for a commercial entity, but it was a key component of the cash runway.

When assessing potential one-time revenue, the most significant recent financial event wasn't an IP sale, but rather a major litigation settlement. Talis Biomedical entered into a settlement agreement dated August 29, 2024, to resolve securities class action litigation related to its February 2021 initial public offering (IPO). The total settlement contribution is $32.5 million. Here's the quick math on that: the company's insurance carriers were expected to fund about $5 million, leaving the remaining $27.5 million to be paid from the company's cash reserves. What this estimate hides is the immediate impact on the balance sheet, as that cash outflow was a critical, non-recurring event.

Given the company's status as a 'public shell' due to suspended research and development activities, the current revenue generation is extremely limited, making these historical and one-time figures the most relevant data points for understanding past cash inflows.

Here is a snapshot of the key financial figures related to Talis Biomedical Corporation's recent revenue and financial events:

Metric	Amount	Period/Context
TTM Revenue	$408.00K	Twelve months ending June 30, 2024
Annual Revenue (2023)	$2.13M	Year 2023
NIH Grant Funding (Past)	$0.5 million	Q2 2023 [as provided in outline]
Securities Litigation Settlement	$32.5 million	Settlement contribution dated August 29, 2024
Settlement Paid from Cash Reserves	$27.5 million	Portion of settlement funded by company cash

The revenue streams, as they stood near the end of 2025, can be summarized by the nature of these inflows:

• Minimal TTM revenue from grants or non-core sales.
• Past reliance on NIH grant funding sources.
• Significant, non-recurring cash event from litigation settlement.
• Current revenue generation is effectively near zero from core operations.

Finance: draft 13-week cash view by Friday.